Foundayo™ (Orforglipron)
Orforglipron oral tablets
The only oral non-peptide GLP-1. No injections, no refrigeration, no food timing restrictions.
Legacy treatment library entry
This page is educational. The active Varus flow starts with labs or uploaded results, then moves into clinician review and a care plan before treatment checkout is shown.
About Foundayo™ (Orforglipron)
Foundayo (orforglipron) is an FDA-approved prescription medicine used along with a reduced-calorie diet and increased physical activity to reduce excess body weight and help maintain weight reduction in adults with obesity (BMI >= 30), or adults with overweight (BMI >= 27) who also have a weight-related medical condition. Foundayo is not for cosmetic weight loss.
For Varus's GLP-1 weight-management category, FDA-approved options like Foundayo are the primary path when clinically appropriate. Developed by Eli Lilly, Foundayo is an oral, non-peptide GLP-1 receptor agonist. Because it is a small molecule rather than a peptide, it does not require injection or refrigeration.
In the ATTAIN clinical program, adults taking Foundayo with diet and exercise experienced greater average weight loss than placebo over 72 weeks. Exact results varied by dose and study population, and individual results may vary.
Important Safety Information: Foundayo has boxed-warning considerations related to thyroid C-cell tumors observed with GLP-1 receptor agonists in rodents. It should not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Common side effects include nausea, constipation, diarrhea, and vomiting. Foundayo may reduce the effectiveness of oral contraceptives; talk to your provider about alternative or backup contraception. Foundayo should not be used during pregnancy.
How it works
Unlike injectable GLP-1 agonists (which are peptides), orforglipron is a non-peptide small molecule. It binds to and activates the GLP-1 receptor, triggering appetite reduction, improved satiety, and metabolic benefits.
The key advantage is oral bioavailability — the molecule is stable in stomach acid and readily absorbed through the gut lining, eliminating the need for injection. Dosing starts low and gradually increases over several weeks to help minimize gastrointestinal side effects.
What happens after this library page
Diagnostics or uploaded-lab review
Metabolic care starts with current biomarker context or a clinician-reviewed upload of recent labs.
Clinician eligibility review
A clinician reviews contraindications, treatment goals, and lab context before any medication recommendation is shown.
Care plan before checkout
Treatment options, if recommended, are presented after care-plan review in a separate treatment transaction.
Monitoring cadence
Follow-up labs and ongoing review are matched to the treatment plan and biomarker profile.
Frequently asked questions
Important Safety Information
- Orforglipron carries boxed-warning considerations related to thyroid C-cell tumors and should not be used in patients with a personal or family history of MTC or MEN2.
- Common side effects include nausea, constipation, diarrhea, and vomiting.
- Orforglipron may reduce the effectiveness of oral contraceptives and should not be used during pregnancy.
- Foundayo is not for cosmetic weight loss.
Medical services are provided by independent licensed clinicians using the Varus platform. Varus does not provide medical advice, diagnosis, or treatment. Compounded medications are prepared by licensed pharmacies and are not FDA-approved. Individual results may vary. This information is for educational purposes and does not constitute medical advice.